Cytochrome P450 3A4 (CYP3A4)

Where the papers sit

10 papers from the last 6 months study Cytochrome P450 3A4 (CYP3A4) directly · updated from PubMed 3 Oct 2026

• CYP3A4 Drug Interaction Prediction

  PBPK models are being refined to quantify CYP3A4-mediated drug-drug interactions and the fraction of clearance attributable to CYP3A4. Simvastatin, simvastatin acid, midazolam, siponimod and ziftomenib anchor comparisons with clinical data, inhibitors and grapefruit juice. The recurring goal is to replace isolated interaction studies with model-based prediction of exposure and fmCYP3A4. Agreement with clinical observations is encouraging, but compound-specific metabolism and inhibitor effects remain open.

  4 papers · 40%

• Cytochrome P450 Interaction Screening

  CYP inhibition work is moving toward integrated prediction and confirmation across enzymes, substrates and clinical exposure. DeepCYP models pathway, site and product outcomes, while microsome and clinical studies test inhibitors such as polyphyllin VII and bemnifosbuvir across CYP2C19, CYP2D6, CYP2E1 and CYP3A4. The shared endpoint is earlier identification of metabolic liabilities and drug-drug interaction risk. Experimental breadth and clinical validation remain necessary because in vitro inhibition does not always predict patient exposure.

  3 papers · 30%

• Others — Cancer Biology and Pharmacology

  Breast-cancer niche biology, CYP3A pharmacogenetics and doxorubicin delivery appear here as separate translational lines. The cancer study links PROM1+SMAD5+ tumor-initiating cells to premetastatic niches through spatial multi-omics and tumor-microenvironment signaling. A separate pharmacogenetic study tests CYP3A-related variants using the 4β-hydroxycholesterol/cholesterol ratio, while polymer micelles seek to improve oral doxorubicin absorption. These topics share a pharmacology-and-cancer context but do not support one common direction.

  3 papers · 30%